Factors related to primary cancer death and non-primary cancer death in patients treated with stereotactic body radiotherapy for pulmonary oligometastases

被引：1

作者：

Yamamoto, Takaya ^{[1
]}

Niibe, Yuzuru ^{[2
,3
]}

Matsumoto, Yasuo ^{[4
]}

Aoki, Masahiko ^{[5
]}

Oh, Ryoong-Jin ^{[6
]}

Ozaki, Masatoki ^{[7
]}

Kobayashi, Mitsuru ^{[8
]}

Manabe, Yoshihiko ^{[9
]}

Shintani, Takashi ^{[10
]}

Dekura, Yasuhiro ^{[11
]}

Onishi, Hiroshi ^{[12
]}

Yamashita, Hideomi ^{[13
]}

Jingu, Keiichi ^{[1
]}

机构：

[1] Tohoku Univ, Grad Sch Med, Dept Radiat Oncol, Sendai, Miyagi, Japan

[2] Toho Univ, Dept Radiol, Omori Med Ctr, Tokyo, Japan

[3] Kurume Univ, Dept Publ Hlth, Sch Med, Kurume, Fukuoka, Japan

[4] Niigata Canc Ctr, Dept Radiat Oncol, Niigata, Japan

[5] Hirosaki Univ, Dept Radiat Oncol, Hirosaki, Aomori, Japan

[6] Miyakojima IGRT Clin, Dept Radiol, Osaka, Japan

[7] Shizuoka City Shimizu Hosp, Dept Radiat Oncol, Shizuoka, Japan

[8] Fukuyama City Hosp, Dept Radiat Oncol, Fukuyama, Hiroshima, Japan

[9] Nagoya City Univ, Dept Radiol, Nagoya, Aichi, Japan

[10] Kyoto Univ, Grad Sch Med, Dept Radiat Oncol & Image Appl Therapy, Kyoto, Japan

[11] Keiyu Kai Sapporo Hosp, Dept Radiat Oncol, Sapporo, Hokkaido, Japan

[12] Yamanashi Univ, Dept Radiol, Chuo, Japan

[13] Univ Tokyo, Dept Radiol, Tokyo, Japan

来源：

CANCER MEDICINE | 2020年 / 9卷 / 23期

关键词：

cancer‐ specific death; non‐ primary cancer death; pulmonary oligometastases; stereotactic body radiotherapy; RADIATION-THERAPY; POOLED ANALYSIS; LUNG; METASTASECTOMY; SURVIVAL; MORTALITY; SMOKING; TRIAL; HEAD; SBRT;

D O I：

10.1002/cam4.3508

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cancer-specific death (CSD) and non-cancer-specific death (non-CSD) after stereotactic body radiotherapy (SBRT) for pulmonary oligometastases have not been studied in detail. The aim of this study was to determine the cumulative incidences of CSD and non-CSD and to reveal prognostic factors. Data from a large survey of SBRT for pulmonary oligometastases were used for analyses, and patients with unknown cause of death were excluded from current analyses. CSD was primary cancer death and non-CSD was non-primary cancer death including a series of cancer treatment-related deaths. Cumulative incidences were calculated using the Kaplan-Meier method and a stratified Cox regression model was used for multivariate analyses (MVA). Fifty-two patients with an unknown death were excluded and a total of 1326 patients was selected. CSD and non-CSD occurred in 375 and 109 patients, respectively. The median OS period was 53.2 months and the cumulative incidences of 1-, 3-, and 5-year CSD vs. non-CSD rates were 6.5% vs. 2.3%, 29.5% vs. 8.6%, and 41.2% vs. 11.0%, respectively. In MVA, the incidence of CSD was related to performance status (1 vs. 0; p < 0.001, 2-3 vs. 0; p = 0.011), oligometastatic state (sync-oligometastases vs. oligo-recurrence, p = 0.026) and maximum tumor diameter (p = 0.009), and the incidence of non-CSD was related to age (p = 0.001), sex (p = 0.030), performance status (2-3 vs. 0; p = 0.002), and irradiated tumor-located lung lobe (left lower lobe vs. other lobes, p = 0.036). CSD was main cause of death, but non-CSD was not rare after SBRT. Prognostic factors for CSD and non-CSD were different, and an understanding of the factors would help in treatment.

引用

页码：8902 / 8911

页数：10

共 32 条

[1] Cardiac Radiation Dose, Cardiac Disease, and Mortality in Patients With Lung Cancer [J].